It is clear however that IFNγ does possess anti-viral properties in humans, with rIFNγ treatment of a human pulmonary epithelial cell line effective at limiting SARS-CoV-2 infection in vitro62,92,93 and subcutaneous rIFNγ treatment of a small group of moderately ill COVID-19 patients associated with reduced time to hospital discharge29. This evidence concerns the gene IFNG and COVID-19.